Analysts expect Mereo BioPharma Group plc to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 500,000.00, a 91.6% miss against the 5.98 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 48.01 M | 0.00 | 10.00 M | 0.00 | 500,000.00 | - | - | ||
| High Estimate | 25.26 M | 0.00 | 9.66 M | 18.50 M | 6.55 M | 0.00 | 15.35 M | ||
| Low Estimate | 21.66 M | 0.00 | 8.35 M | 15.73 M | 5.41 M | 0.00 | 12.61 M | ||
| Consensus Estimate | 23.46 M | 0.00 | 9.00 M | 17.12 M | 5.98 M | 0.00 | 13.98 M |
Analysts expect Mereo BioPharma Group plc to report earnings per share of -0.06 for 2026, against a range of -0.07 to -0.05. The most recent reported year, 2025, came in at -0.05, a 16.7% beat against the -0.06 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.07 | -0.07 | -0.04 | -0.06 | -0.05 | - | - | ||
| High Estimate | -0.06 | -0.08 | -0.04 | -0.06 | -0.06 | -0.05 | -0.03 | ||
| Low Estimate | -0.06 | -0.08 | -0.04 | -0.06 | -0.06 | -0.07 | -0.03 | ||
| Consensus Estimate | -0.06 | -0.08 | -0.04 | -0.06 | -0.06 | -0.06 | -0.03 |